Kronos Bio, Inc. Overview
Pro stress-test →Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer, focusing on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. The company was recently acquired by Concentra Biosciences in May 2025, marking a significant transition in its corporate structure.
Strategic Profile
Pro stress-test →The company's lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML), and is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors. The platform focuses on modulating historically difficult-to-target cancer pathways.
Competitive Landscape
Pro stress-test →Kronos Bio competes in the oncology-focused precision medicine space alongside companies developing targeted cancer therapeutics. Competitors include both large pharmaceutical companies and specialized biotech firms developing CDK inhibitors, SYK inhibitors, and transcription factor modulators. The company's niche focus on dysregulated transcription factors provides some differentiation in a crowded immuno-oncology landscape.
Industry Context
Kronos Bio, Inc. operates in Biopharmaceuticals/Oncology - Clinical-stage drug development, precision medicine.
Key facts
Founded: 2017 · Headquarters: Cambridge, MA · Employees: 8